Warsaw

• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending
  2025-523510-87-00 5 Obesity
• A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower-risk MDS in ESA-naïve adults who require RBC … Pending
  2025-523544-12-00 5 Myelodysplastic neoplasms/syndromes (MDS)
• A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t … Pending
  2025-523555-66-00 5 Myelofibrosis
• An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants with Rheumatoid Arthritis Pending
  2025-523579-47-00 4 moderate to severe rheumatoid arthritis (RA)
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 4 Homeostatic iron regulator gene-related hereditary hemochromatosis
• A Multicenter, Open-Label, Dose Escalation Study of the Safety, Tolerability, and Efficacy of Budiodarone for the Treatment of Subjects with … Pending
  2025-523860-19-00 10 Non-permanent Atrial Fibrillation
• Identification of mitochondrial biomarkers reflecting omaveloxolone treatment (in FA patients) Pending
  2025-523881-26-00 6 Friedreich's ataxia
• Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer Pending
  2025-523972-21-00 7 Extensive-Stage Small Cell Lung Cancer
• A study to assess the safety and efficacy of different doses of ELV001 to treat active rheumatoid arthritis in patients with an inadequate r … Pending
  2025-524005-32-00 4 Rheumatoid arthritis
• Phase I study of CDK8 inhibitor RVU120 in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma … Pending
  2025-524031-39-00 3 Medulloblastoma (recurrent or progressive)
• An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzyme … Pending
  2025-524060-38-00 3 Active Ulcerative Colitis (UC)
• A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Pending
  2025-524078-40-00 5 Chronic Spontaneous Urticaria
• BETRI-Prospective: Asthma control in Single Inhaler ICS/LABA/LAMA (87/5/9 pMDI [BDP/FF/GB - 100/6/12.5 µg]) vs Single Inhaler ICS/LABA (200/ … Pending
  2025-524289-56-00 6 Asthma
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending
  2025-524316-11-00 5 Primary Progressive Multiple Sclerosis (PPMS)
• A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in … Pending
  2025-525127-27-00 9 Generalized Myasthenia Gravis
• Clinical trial (study) comparing the efficacy and safety of mifamurtide versus standard treatment containing sorafenib in pediatric and youn … Pending
  2026-525223-24-00 4 Relapsed/refractory osteosarcoma, High-grade osteosarcoma
• Efficacy and Tolerability of N-AVD compared to BrECADD in patients with advanced Hodgkin Lymphoma (N-BRAVE) Pending
  2026-525263-41-00 5 Hodgkin lymphoma
• A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis Recruiting
  2025-523950-15-01 4 2026-05-29 Generalized Myasthenia Gravis
• A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease Recruiting
  2025-522001-38-00 4 2026-05-27 Crohn’s Disease
• Phase 1b Study of Tarlatamab + ZL-1310 +/- Anti-PD-L1 in Small Cell Lung Cancer Recruiting
  2025-522888-15-00 3 2026-05-27 Small Cell Lung Cancer
• Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting
  2023-503766-24-00 11 2026-05-26 Moderate to Severe Plaque Psoriasis
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants with Pruri … Recruiting
  2025-523404-74-00 4 2026-05-26 Prurigo Nodularis
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting
  2025-523106-32-00 5 2026-05-25 Obesity or Overweight and Type 2 Diabetes

Showing 97–120 of 1,708 trials